Department of Gastrointestinal Surgery, Qingdao University Affiliated Hospital
Qingdao, Shandong, 266000, China
NCT Number: NCT05352802
The GISSG+2201 study was launched by Shandong Gastrointestinal Surgery Study Group (GISSG). The intention is to establish a multimodal prehabilitation protocol in frail elderly patients who undergo gastric cancer radical surgery, explore the feasibility and effectiveness of the measures and evaluate the effect of program on short-term clinical outcome, recovery index and the long-term tumor-related outcome.
This study is active but is not currently recruiting participants.
Notify Me65 year–85 year
All sexes
Interventional
Not applicable
Qingdao, Shandong, 266000, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Multimodal prehabilitation programs have adopted planned, structural, repetitive and purposeful approach that includes elements of exercise, nutritional and psychological.
The core content is to adopt a series of optimized measures performed during the perioperative period on the basis of evidence-based medical findings to reduce the physiological and psychological stress of patients and to accelerate their recovery.
Time frame: Postoperative (≤30 days after surgery)
Major postoperative complications of patients with Gastrointestinal malignancy included gastrointestinal complication, surgical site complication, respiratory complication, cardiovascular complication, thromboembolic complication, urinary complication and other complications. The severity of complications was recorded and classified according to Clavien-Dindo classification score.
Time frame: Baseline (T0), Post-intervention (up to 2 weeks), and POD 30(30 days after surgery)
The 6-minute walk test (6MWT) can be used to measure exercise capacity to reflect cardio-pulmonary function.
Time frame: Baseline (T0), Post-intervention (up to 2 weeks), and POD 30(30 days after surgery)
QoL comprises patient-reported outcomes (PRO) of physical symptoms and psychosocial health status. Quality of Life Questionnaire (QLQ) C30 is sensitive tool for measuring individual performance status. Each index score ranges from 1 to 4, with higher scores indicating higher risk.
Time frame: Baseline (T0), Post-intervention (up to 2 weeks), and POD 30(30 days after surgery)
Interleukin, Tumor necrosis factor and C-reactive protein serum concentrations
Time frame: Postoperative (≤30 days after surgery)
Postoperative pain severity, postoperative delirium severity and occurrence, first exhaust and defecation, ureteral catheter removal, abdominal drainage tubes removal, postoperative hospital stay, hospitalization costs, 30-day all-cause mortality and 30-day hospital readmission rate.
Time frame: 3 years
3-year recurrence-free survival (RFS) rate and 3-year overall survival (OS) rate.
The Affiliated Hospital of Qingdao University
Other
Supervised Home-based Multimodal Prehabilitation to Improve the Clinical Outcomes of Frail Elderly Patients With Gastric Cancer: Multicenter Randomized Controlled Trial (GISSG+2201)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06157892
Advanced Breast Cancer, Advanced Gastric Cancer
Tucson, Arizona, United States
View Trial DetailsNCT07113340
Digestive System Diseases, Digestive System Neoplasms
Qingdao, Shandong, China
View Trial DetailsNCT03979131
Digestive System Diseases, Digestive System Neoplasms
Barcelona, Spain
View Trial DetailsNCT01133951
Bacterial Infections, Bacterial Infections and Mycoses
Yangzhong, Jiangsu, China
View Trial Details